Previous 10 | Next 10 |
2023-05-23 17:14:55 ET Gainers: Reata Pharmaceuticals ( RETA ) +10% . Urban Outfitters ( URBN ) +7% . COMPASS Pathways ( CMPS ) +6% . Stitch Fix ( SFIX ) +5% . TScan Therapeutics ( TCRX ) +4% . Losers: PTC The...
FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other c...
Anticipated FDA action date in Q4 2023; if approved, combined launch for Erosive GERD and H. pylori indications planned before year end If approved, vonoprazan would be the first innovative acid suppressant from a new drug class approved for the treatment of Erosive GERD in the U.S. i...
2023-05-11 10:00:13 ET Gainers: Organogenesis ( ORGO ) +23% . Arcturus Therapeutics ( ARCT ) +14% . Phathom Pharmaceuticals ( PHAT ) +14% . Pulse Biosciences ( PLSE ) +13% . PharmaCyte Biotech ( PMCB ) +11% . Losers: ImmunityBi...
2023-05-11 09:37:36 ET Phathom Pharmaceuticals ( NASDAQ: PHAT ) added ~8% on Thursday morning after Evercore ISI upgraded the biopharma, citing a potential FDA approval for its initial product candidate, vonoprazan, targeted at gastrointestinal disorders. “Phathoms...
FLORHAM PARK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2023 and provided upda...
Higher H. pylori eradication rates demonstrated with vonoprazan-based regimens vs. lansoprazole triple therapy, regardless of different baseline demographics and clinical characteristics Meta-analysis shows potassium-competitor acid blockers (PCABs), including vonoprazan, provide a long...
2023-04-25 08:00:00 ET Summary Phathom Pharmaceuticals, Inc. received a pair of CRLs that look fairly resolvable. If resolved, Phathom Pharmaceuticals will have vonoprazan launch in two indications, one very large, in Q4. They should have enough cash and loans to survive until...
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) is one of today's top gainers. The company's shares are currently up 14.51% on the day to $10.02. Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal di...
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the fo...
News, Short Squeeze, Breakout and More Instantly...
Phathom Pharmaceuticals Inc. Company Name:
PHAT Stock Symbol:
NYSE Market:
Phathom Pharmaceuticals Inc. Website:
VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD) VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid reduction of heartburn with daily treatment VOQUEZNA repre...
2024-06-23 22:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...